Literature DB >> 1623937

Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen.

R Blakytny1, J J Harding.   

Abstract

Evidence from epidemiological, in vitro and animal studies has accumulated to support the idea that aspirin, ibuprofen and paracetamol protect against cataract. In this study rats made diabetic with streptozotocin were given these drugs in their drinking solution for up to 160 days. All three drugs delayed cataract formation assessed by slit-lamp examination for a large part of this time. Blood glucose levels were a little lower in diabetic rats treated with aspirin and ibuprofen than in untreated diabetic rats although all groups remained diabetic. Similarly, the increased glycation (non-enzymic glycosylation) of lens proteins caused by diabetes was less in the diabetic rats treated with aspirin and ibuprofen. The fall in glutathione induced by diabetes was also alleviated by aspirin and ibuprofen. Paracetamol appeared to afford similar protection against the biochemical changes but its effect was not statistically significant. The decrease in glutathione and increase in glycation were related to the progression of lens opacification. The greatest loss of glutathione occurred at an early stage, whereas glycation had its greatest change at the later stages--nuclear and mature cataract. These results encourage the view that ibuprofen, aspirin and paracetamol could protect against cataract in man: a hypothesis that could be tested in a properly-conducted clinical trial.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623937     DOI: 10.1016/0014-4835(92)90129-g

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  20 in total

1.  Comparison of lens oxidative damage induced by vitrectomy and/or hyperoxia in rabbits.

Authors:  Hong Yan; Dan Wang; Tian-Bing Ding; Hai-Yan Zhou; Wei-Jia Yan; Xin-Chuan Wang
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

2.  Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase.

Authors:  H Yan; J J Harding
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

3.  The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritin.

Authors:  A D Mumford; I A Cree; J D Arnold; M C Hagan; K C Rixon; J J Harding
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

4.  Free alanine, aspartic acid, or glutamic acid reduce the glycation of human lens proteins.

Authors:  S Ramakrishnan; K N Sulochana; R Punitham; K Arunagiri
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

Review 5.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

6.  Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac.

Authors:  C Marques; J S Ramalho; P Pereira; M C Mota
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

Review 7.  Implications of treatment that target protective mechanisms against diabetic nephropathy.

Authors:  Akira Mima; Weier Qi; George L King
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

8.  Glutathione adducts, not carbamylated lysines, are the major modification of lens alpha-crystallins from renal failure patients.

Authors:  J B Smith; G A Shun-Shin; Y Sun; L R Miesbauer; Z Yang; Z Yang; X Zhou; J Schwedler; D L Smith
Journal:  J Protein Chem       Date:  1995-04

9.  Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats.

Authors:  Qiong Shi; Hong Yan; Ming-Yong Li; John J Harding
Journal:  Mol Vis       Date:  2009-10-21       Impact factor: 2.367

10.  Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats.

Authors:  Hong Yan; Yong Guo; Jie Zhang; Zhenghua Ding; Wenjing Ha; J J Harding
Journal:  Mol Vis       Date:  2008-12-11       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.